While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Moderna (NasdaqGS:MRNA) initiated the dosing for its innovative mRNA-4106 cancer therapy in a Phase 1 trial, signaling ongoing advancements in their oncology pipeline. However, the company's stock ...

Q1 2025 Earnings Call Transcript May 15, 2025 Omeros Corporation misses on earnings expectations. Reported EPS is $-0.65 EPS, expectations were $-0.57. Jennifer Williams – Investor and Media relations ...

Tell us about the product or service that Inductive Bio offers.

Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

“This is the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which ...

May 15, 2025TriSalus Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.33 EPS, expectations were $-0.2. , IR: Mary Szela - President and CEO James Young - CFO Richard Marshall - ...

Subungual melanoma which appears under fingernails and toenails, is a rare but serious form of skin cancer that typically isn ...

At some point in everyone’s life, they go down the vitamin route – whether because they have a restrictive diet and need ...